Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Long on Sequencing Local Therapy in Patients With Melanoma Who Have Brain Mets

October 21st 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the sequence of local therapy in patients with melanoma who have brain metastases.

Dr. Weber on Toxicity Data From CheckMate-238 Trial in Melanoma

October 18th 2019

Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma

October 15th 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the CheckMate-204 trial in melanoma.

Dr. Long on Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

October 12th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the long-term data from the phase II ABC study , in which investigators are comparing the efficacy of nivolumab in combination with ipilimumab versus single-agent nivolumab in patients with melanoma brain metastases.

Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma

October 8th 2019

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

New Data Establish Long-Term Efficacy for 2 Modern Modalities in NSCLC and Melanoma

October 4th 2019

For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.

Dr. Atkins on CA209-004 Trial Results in Advanced Melanoma

October 3rd 2019

Michael B. Atkins, MD, discusses results from the CA209-004 trial, which was a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab plus ipilimumab.

Merkel Cell Carcinoma Study Matches TMB With Disease Drivers

October 3rd 2019

The molecular profile of Merkel cell carcinoma differs depending upon whether the malignancy is driven by ultraviolet light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.

ESMO 2019: Dr. Bekaii-Saab Highlights Important Trials in GI Malignancies

September 29th 2019

ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer

September 29th 2019

ESMO 2019: Dr. McGregor Highlights Impactful 2019 Prostate Cancer Studies

September 29th 2019

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer

September 29th 2019

ESMO 2019: Dr. Rugo Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

September 29th 2019

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019